| Neuralstem Updates ALS Clinical Trial Progress | ||||
|
|
Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia...
Διαβάστε ολόκληρο το άρθρο στο Medical News Today
|
